Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing-Reference-Cited by-同舟云学术

Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing

Published:2010-08 Issue:9 Volume:32 Page:1597-1609
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Stubenrauch Kay,Wessels Uwe,Birnboeck Herbert,Ramirez Francisco,Jahreis Angelika,Schleypen Julia

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference27 articles.

1. Monoclonal antibodies as innovative therapeutics;Reichert;Curr Pharm Biotechnol,2008

2. Fully human antibodies from transgenic mouse and phage display platforms;Lonberg;Curr Opin Immunol.,2008

3. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products;Koren;J Immunol Methods,2008

4. Strategies and assays for the assessment of unwanted immunogenicity;Wadhwa;J Immunotoxicol,2006

5. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products;Mire-Sluis;J Immunol Methods,2004

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitigating target interference challenges in bridging immunogenicity assay to detect anti-tocilizumab antibodies;Bioanalysis;2024-06-17

2. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis;Rheumatology;2024-03-29

3. Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study;RMD Open;2024-02

4. Application of DNA-based hydrogels as drug delivery system for immunomodulatory therapy;Journal of Drug Delivery Science and Technology;2023-09

5. How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?;Frontiers in Immunology;2021-11-01